Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Citric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA4 | P22748 | 3/20 | 0.84 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CASP1 | P29466 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Citric Acid SCHEMBL30457906 | 1.00 | CA4 (0.84) | CA4ALDH1A1CASP1 | |
| Citric Acid SCHEMBL6387463 | 0.97 | CA4 (0.89) | CA4ALDH1A1CASP1 | |
| Citric Acid SCHEMBL4957183 | 0.97 | CA4 (0.89) | CA4ALDH1A1CASP1 | |
| Citric Acid SCHEMBL4958369 | 0.97 | CA4 (0.89) | CA4ALDH1A1CASP1 | |
| Citric Acid SCHEMBL216857 | 0.97 | CA4 (0.89) | CA4ALDH1A1CASP1 | |
| Citric Acid SCHEMBL6259823 | 0.94 | CA4 (0.84) | CA4ALDH1A1CASP1 | |
| Citric Acid SCHEMBL14335789 | 0.94 | CA4 (0.84) | CA4ALDH1A1CASP1 | |
| Citric Acid SCHEMBL22556628 | 0.94 | CA4 (0.84) | CA4ALDH1A1CASP1 | |
| Citric Acid SCHEMBL28616729 | 0.94 | CA4 (0.84) | CA4ALDH1A1CASP1 | |
| Citric Acid SCHEMBL15667258 | 0.94 | CA4 (0.84) | CA4ALDH1A1CASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260077020-A1 | ORAL PEPTIDE PHARMACEUTICAL COMPOSITION THAT FACILITATES ENHANCED ORAL ABSORPTION | LE ROUX DANIELLE MARIE (US) | 2026-03-19 | — | — | US | claimed |
| CN-116102064-B | Clean production high-purity V2O5Is a method of (2) | 大连融科储能集团股份有限公司 | 2024-12-20 | — | — | CN | claimed |
| CN-117702133-A | Synthesis method and application of bismuth vanadate electrode with adjustable phase composition | 中国科学院大连化学物理研究所 | 2024-03-15 | — | — | CN | claimed |
| EP-3509573-B1 | PHARMACEUTICAL COMPOSITIONS FOR DELIVERY OF PEPTIDE | ANYA BIOPHARM INC (TW) | 2023-05-24 | — | — | EP | claimed |
| CN-116102064-A | Clean production high-purity V 2 O 5 Is a method of (2) | 大连融科储能集团股份有限公司 | 2023-05-12 | — | — | CN | claimed |
| US-11389474-B2 | Pharmaceutical compositions for delivery of peptide | ANYA BIOPHARM INC. (CN) | 2022-07-19 | — | — | US | claimed |
| CN-113488641-A | Rapid preparation method of lithium ion battery anode material vanadium pentoxide nanosheet | 三峡大学 | 2021-10-08 | — | — | CN | claimed |
| CN-113461056-A | Preparation method of lithium ion battery negative electrode material hollow porous vanadium pentoxide microspheres | 三峡大学 | 2021-10-01 | — | — | CN | claimed |
| US-20200121796-A1 | PHARMACEUTICAL COMPOSITIONS FOR DELIVERY OF PEPTIDE | ANYA BIOPHARM INC. (CN) | 2020-04-23 | — | — | US | claimed |
| EP-3509573-A1 | PHARMACEUTICAL COMPOSITIONS FOR DELIVERY OF PEPTIDE | Anya Biopharm Inc. (TW) | 2019-07-17 | — | — | EP | claimed |
| WO-2019058273-A1 | PHARMACEUTICAL COMPOSITIONS FOR DELIVERY OF PEPTIDE | ANYA BIOPHARM INC. (TW) | 2019-03-28 | — | — | WO | claimed |
| US-8263232-B2 | Composite coated zinc-containing plated steel material superior in corrosion resistance, blackening resistance, coating adhesion, and alkali resistance | NIPPON STEEL CORPORATION (JP) | 2012-09-11 | — | — | US | claimed |
| US-5045316-A | Pharmaceutical compositions and their use | KAPLAN EPHRAIM (IL) | 1991-09-03 | — | — | US | claimed |
| EP-0274404-A1 | Pharmaceutical compositions and their use | Kaplan, Ephraim (IL) | 1988-07-13 | — | — | EP | claimed |
| US-20260077020-A1 | ORAL PEPTIDE PHARMACEUTICAL COMPOSITION THAT FACILITATES ENHANCED ORAL ABSORPTION | LE ROUX DANIELLE MARIE (US) | 2026-03-19 | — | — | US | disclosed |
| CN-119797425-A | Vanadium-based oxide positive electrode material for water-based zinc ion battery and preparation method thereof | 桂林理工大学 | 2025-04-11 | — | — | CN | disclosed |
| US-12208118-B2 | Pharmaceutical compositions for delivery of peptide | ANYA BIOPHARM INC. (CN) | 2025-01-28 | — | — | US | disclosed |
| EP-0274404-A1 | Pharmaceutical compositions and their use | Kaplan, Ephraim (IL) | 1988-07-13 | — | — | EP | disclosed |
| US-4466947-A | Denitration catalyst and denitrating method | MITSUBISHI PETROCHEMICAL CO. LTD. (JP) | 1984-08-21 | — | — | US | disclosed |
| US-3959297-A | AMMOXIDATION OF 2-METHYL-5-ETHYLPYRIDINE; METAL OXIDE CATALYST | SHOWA DENKO KABUSHIKI KAISHA (JA) | 1976-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260077020-A1 | ORAL PEPTIDE PHARMACEUTICAL COMPOSITION THAT FACILITATES ENHANCED ORAL ABSORPTION | VIP, GIPR, SLC10A2 | CA4 65/4885ALDH1A1 4359/4885CASP1 3055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.